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Abstract
Background. There are approximately 15.5 million individuals alive today in the U.S. 
with a personal history of cancer. For this large and growing population, ill effects 
associated with cancer diagnosis and treatment include both physical and psychosocial 
symptoms adversely affecting quality of life. One low-risk alternative to conventional 
pharmaceutical use in treating these symptoms is mindfulness practice. Research on self-
reported measures provides strong evidence that this type of intervention improves 
quality of life for cancer survivors, but evidence of impact on objective measures is 
limited. Cortisol, the body’s primary stress hormone, is one relatively easy to measure 
indicator that has been increasingly favored. 
Methods. In this randomized controlled trial, 38 cancer survivors from the Greenville 
Health System in South Carolina were assigned to either a 4-week mindfulness 
intervention program or a control group. Six salivary cortisol samples were collected daily 
at baseline, 6 weeks, and 12 weeks, along with questionnaire data assessing a variety of 
symptoms and lifestyle behaviors. 
Both rhythm, as the change in cortisol over the day, and absolute levels of cortisol 
were modelled using multivariable linear regression. Specifically, for absolute levels, a 
treatment effect by categorization at baseline of those with high, normal, and low cortisol 
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levels was modelled using an interaction between treatment and baseline levels of 
cortisol. 
Results. None of the explored self-report or demographic variables assessed were 
significantly associated with diurnal cortisol decline at baseline in either the crude or 
adjusted models. Although non-significant, the intervention was associated with a greater 
cortisol decline over the day (-1.79 {p=0.52} and -2.71 {p=0.23} respectively for 6 and 12-
week follow-up) which has been previously associated with better survival outcomes for 
cancer patients. No significant or consistent directional results were observed when 
examining effect modification of baseline cortisol categorizations on change in cortisol 
levels. 
Conclusions. Although the effect size was relatively large, our analysis did not show a 
significant impact of the mindfulness intervention program on change in cortisol decline 
or in changes in absolute levels of cortisol as a function of baseline categorization. Our 
results add to the accumulating literature surrounding the use of alternative medicine 
practices for symptom treatment in cancer survivors and provide recommendations for 
future work using cortisol to assess impact of mindfulness interventions.  
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Chapter 1: Introduction 
1.1 Statement of Problem 
In the United States, the current lifetime chance of developing cancer is almost 1 
in every 2 persons for men and more than 1 in 3 for women1. With incidence rates 
remaining steady for the past decade, and with large improvements in survival due to 
early detection methods and better treatment, the population of cancer survivors in the 
U.S. is substantial (American Cancer Society, 2016). Current estimates suggest that there 
are approximately 15.5 million individuals with a personal history of cancer alive today in 
the U.S. and that that population is expected to reach 20 million by the year 2026 (K. D. 
Miller et al., 2016). For this large and growing population, the distress and uncertainty 
associated with diagnosis and treatment of cancer is related to both physical and 
psychosocial symptoms adversely affecting quality of life including anxiety, depression, 
fear of recurrence, stress, pain, insomnia, and fatigue in addition to long-term side effects 
of surgery and adjuvant therapies (Linda E. Carlson, 2016). 
Addressing these issues is not only vital to creating high quality of life for this 
sizeable portion of the U.S. population, but failing to manage stress symptoms has been 
linked to harmful lifestyle behaviors such as overeating, alcohol or drug abuse, disrupted 
sleep, and physical inactivity and associated adverse health outcomes (McEwen, 2008). 
Pharmacological approaches to mitigate stress, anxiety, and sleep disturbance have 
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potentially disruptive or dangerous side effects, while evidence for the effectiveness of 
low risk complementary and alternative medicine practices to treat both psychosocial and 
physical symptoms in cancer survivors has gained traction in recent years. One such 
intervention that is well established for use in cancer populations is Mindfulness Based 
Stress Reduction (MBSR); a program developed in the 1990’s by Jon Kabat-Zinn to aid 
individuals in dealing with both physical and emotional distress through the practice of 
mindfulness; or present moment awareness and acceptance (Kabat-Zinn, 1990). 
There is strong, level 1 evidence in the current literature from meta-analyses and 
reviews of randomized controlled trials that MBSR is effective for improving 
psychological, functional, and quality of life outcomes in cancer patients, but this 
evidence relies primarily on self-reported measures of stress, anxiety, mood, and other 
common symptoms (Linda E. Carlson, 2012, 2016; Cramer, Lauche, Paul, & Dobos, 2012; 
Piet, Würtzen, & Zachariae, 2012; Zainal, Booth, & Huppert, 2013). A handful of studies 
have also examined the biomarker cortisol as an indicator of stress and hypothalamic-
pituitary-adrenal (HPA) axis function to assess efficacy of mindfulness interventions in 
cancer survivors. Results and methodology in these studies is not widely consistent, but 
point towards a small beneficial effect of mindfulness interventions on cortisol levels in 
cancer survivors. 
1.2 Purpose and Objectives 
In 2012, the Greenville Health System (GHS) created the Center for Integrative 
Oncology and Survivorship to support and study complementary approaches to cancer 
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survivor care. As part of this, practitioners developed a mindfulness program based on 
Kabat-Zinn’s original MBSR program called Cultivating Mindfulness in Cancer Survivorship 
(CMCS). The CMCS program is an abbreviated 4-week class focusing on meditation 
practices, attention regulation, and emotional control. 
The current study is a randomized controlled trial (RCT) in a sample of cancer 
survivors from GHS who were randomized to attend the CMCS program or a brief 
breathing exercise class. As an exploratory study of the CMCS program offered by GHS, 
this research is meant to provide feedback and preliminary results on effects of the 
intervention on psychometric and physiologic data. Specifically, the purpose in this paper 
is to assess impact of the CMCS mindfulness program on cortisol levels in GHS cancer 
survivors. 
Specific Aim 1 
To assess association of the diurnal cortisol decline (DCD) at baseline with key 
psychosocial variables indicated in the literature by testing the following hypotheses: 
 More negative DCD at baseline will be associated with increased physical activity. 
 More negative DCD at baseline will be associated with being female. 
 More negative DCD at baseline will be associated with younger age. 
 More negative DCD at baseline will be associated with fewer symptoms of 
depression. 
 More negative DCD at baseline will be associated with increased sleep quality. 
 More negative DCD at baseline will be associated with lower perceived stress. 
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 More negative DCD at baseline will be associated with participants in the Fall 
program cohort. 
Specific Aim 2 
To assess association of the GHS mindfulness intervention on diurnal cortisol rhythm 
by testing the following hypothesis: 
 Change in DCD will be more negative in the intervention group, relative to the 
control group, after the intervention. 
Specific Aim 3 
To assess association of the GHS mindfulness intervention on diurnal cortisol levels by 
testing the following hypothesis: 
 The effect of treatment will be modified by patient cortisol level at baseline: those 
with high initial cortisol will see a greater decrease, and those with low initial 
cortisol will see a greater increase in the treatment group relative to the control 
group. 
1.3 Significance of Research 
This research will provide insight to guide development of larger trials of the CMCS 
program at GHS. Furthermore, it will contribute to the literature at large on the 
effectiveness of mindfulness interventions for cancer patients as assessed using the 
objective biomarker cortisol. Investigation of cortisol in this context is relevant as an 
alternative to self-report measures of quality of life indicators such as stress and anxiety. 
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Additionally, abnormal cortisol rhythms and elevated evening cortisol levels have been 
linked with shortened survival time in cancer patients (L. Cohen et al., 2012; Schrepf et 
al., 2015; Sephton et al., 2013; Sephton, Sapolsky, Kraemer, & Spiegel, 2000). Despite this, 
there are few RCTs examining the impact of mindfulness meditation on HPA axis function 
through assessment of diurnal cortisol rhythm in a population of cancer survivors, and 
those that exist provide mixed results. 
1.4 Study Outline 
Within this chapter (Chapter 1) I have briefly reviewed the issues of disruptive 
symptoms in a growing population of cancer survivors, the purpose and primary 
objectives of this research, and the expected contributions to the literature concerning 
both mindfulness interventions and cortisol measures in cancer survivors. 
Chapter 2 will provide an update on the impact of cancer survivorship on both a 
population scale and on an individual level in terms of symptomology and quality of life 
in cancer survivors. I also will briefly cover the concept of mindfulness practice as a tool 
to manage psychosocial response to medical conditions through present moment 
awareness. Additionally, I will introduce the biomarker cortisol as a plausible measure of 
HPA axis function and describe the biological mechanism underlying its release in the 
body. Following this, I will discuss the use of cortisol as an outcome measure in research 
and evaluate the appropriateness of various methods of collection and analysis of cortisol 
to objectively assess HPA axis function and impact of treatment. This background will 
provide the reader with the relevant understanding to critically evaluate the final 
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summary in Chapter 2 of the most relevant literature and to stimulate interest in the 
topic, methodology, analytical process, and results of this study. 
The study design, methodological details, and statistical methods are described in 
Chapter 3 and Chapter 4 will provide results from the data analysis. 
I will conclude in Chapter 5 with a discussion of relevant findings and their 
implications, including suggestions for future research.
7 
Chapter 2: Background
2.1 Cancer Survivorship 
A cancer survivor is anyone living with a history of cancer diagnosis regardless of 
time since diagnosis, and does not exclude individuals receiving active treatment (Centers 
for Disease Control, 2016; Morgan, 2009). Improvements in cancer screening, diagnosis, 
treatment, and care over the past 50 years have led to a dramatic increase in 5-year 
survival for cancer patients: from 49% between 1975 and 1977 to 69% between 2005-
2011 (SEER 9 Region NCI) (American Cancer Society, 2016). This increase in survival 
coupled with steady incidence rates in the past decade (2003-2012) for women and only 
slightly declining rates for men during that same time period (avg. 1.4% per year) means 
the population of cancer survivors in the United States is large and growing (American 
Cancer Society, 2016). 
Cancer survivorship comes with a range of stressors and potentially lasting 
changes in lifestyle, including disrupted family, job, and social roles, and changes in 
capabilities and appearance in addition to continued side effects of treatments such as 
pain and dysfunction. Many survivors also report a lingering fear of the possibility of 
cancer recurrence, progression, or death (Linda E. Carlson, 2016). Refer to Table 2.1 for a 
categorized listing of potential negative cancer survivorship outcomes from Morgan, 2009 
(Morgan, 2009). 
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Table 2.1 Negative Outcomes of Cancer Survivorship (Morgan, 2009) 
 
Physical Changes Psychological Changes 
Altered body/self-image Changes in family structure 
Cardiac damage secondary to 
anthracycline treatment 
Cognitive changes 
Impaired sexuality Fear of genetic inheritance for families 
Osteoporosis Fear of recurrence 
Pain Financial concerns 
Peripheral neuropathies Loss of ability to work 
Premature menopause Pain 
Secondary cancers Social support 
Stress incontinence Workplace or insurance discrimination 
 
Morgan explains three stages of survivorship: acute, extended, and permanent 
(Morgan, 2009). The stages are not necessarily experienced by all patients, and provide 
only a general timeframe, but each stage comes with its own set of challenges for 
survivors. The acute stage encompasses diagnosis, treatment decisions, and primary 
treatments including surgery, radiation, and/or chemotherapy. The extended stage is the 
follow-up period to completion of primary treatments during which the cancer may be in 
remission; or the patients’ condition is identified as terminal. Finally, the permanent stage 
is the long-term period following remission where probability of recurrence is low and 
survival is expected to be lasting (Morgan, 2009). 
One issue encountered at each stage of cancer survival is the need for emotional 
regulation in response to increased life stressors. One report found that cancer patients 
identified emotional effects of cancer as being more difficult to deal with than either 
physical effects or practical effects (Macmillan Cancer Support, Opinion Leader Research, 
2006). Through development of a Cancer Survivor Core Set, Geerse and colleagues 
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reconfirmed that cancer survivors deal with persistent health and emotional problems 
(Geerse et al., 2017). Geerse and colleagues developed the Cancer Survivor Core Set with 
a panel of experts and healthcare workers to identify health-related problems of 
importance for cancer survivors for practical use in directing long-term care efforts. In this 
Core Set including three components (body function, activities and participation, and 
environmental factors) and 19 separate categories within the components, the category 
for emotional function was the only issue that panelists from prostate, breast, and 
colorectal cancer all rated with 100% content relevance to survivorship care (Geerse et 
al., 2017). 
It is evident that quality of life is an important consideration for cancer survivors 
and that emotional dysregulation is reported to be a major negative outcome of cancer 
survivorship. It is likely that for this reason research into complementary and alternative 
care programs for survivors has been on the rise in recent decades. One such alternative 
care practice that has been implemented and researched in cancer populations is 
mindfulness meditation. 
2.2 Mindfulness Practice 
Mindfulness, or attention to the present moment with an open, accepting 
attitude, as a purposeful practice through meditation has its origins 2,500 years ago in 
Eastern theologies and philosophies. Defining mindfulness and understanding how the 
process of mindfulness operates to improve a broad range of symptoms has been the 
focus of some discussion. Jon Kabat-Zinn explained mindfulness as: “awareness that 
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arises through paying attention, on purpose, in the present moment, non-judgmentally” 
(Kabat-Zinn, 1990). In an effort to understand the mechanism of mindfulness, Shapiro and 
colleagues formulated a model that centers on three axioms: attention, intentionality, 
and non-judgment when processing thoughts and situations and coined the term 
‘reperceiving’ to describe a change in perception without detachment that comes 
through practicing these axioms of mindfulness (Shapiro, Carlson, Astin, & Freedman, 
2006). Shapiro and colleagues linked these axioms with mechanisms of self-regulation, 
exposure, value clarification, and flexibility in thought, emotion, and behavior that are 
likely facilitators in positive health outcomes of psychological and psychosomatic 
symptom relief as well as valuable outcomes in themselves (Shapiro et al., 2006). 
The translation of mindfulness into nonreligious practice for use in clinical 
populations began near the close of the 1970s with Joh Kabat-Zinn’s research into its 
effectiveness for managing anxiety and pain (Kabat-Zinn, 1990). With the development of 
a formal practice for clinical populations through the MBSR program, research in the field 
of mindfulness meditation has grown and offshoots of the MBSR program have 
proliferated. MBSR and other Mindfulness Based Intervention (MBI) programs generally 
incorporate a variety of mindfulness training techniques including meditation and body 
scanning. Body scanning entails focusing on sensation in various parts of the body 
beginning from head down to feet, and meditation promotes attention to the breath 
while acting nonjudgmentally as an outside observer to any intruding thoughts that 
arise(Rush & Sharma, 2016). Formal practice both in groups and alone provides resources 
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and training to develop mindfulness in daily life and promotes the nonjudgmental 
observance of thought processes as a habit. 
Because of the way mindfulness is practiced, and its influence on thought 
processes, mindfulness meditation may be particularly beneficial for cancer patients. 
Linda Carlson describes how many life changes due to cancer diagnosis require emotional-
based coping strategies rather than problem-based coping strategies, particularly post 
active treatment – something many people are less well equipped to deal with (Linda E. 
Carlson, 2016). Evidence supports that experiencing thoughts mindfully, allowing for 
acceptance of the subjective, not necessarily true, nature of thoughts and their transitory 
nature plays some role in alleviating psychological symptoms. In a 2012 narrative review, 
Linda Carlson assessed use of MBIs in cancer populations, concluding that level 1 evidence 
from systematic reviews and meta-analyses of RCTs exists for the effectiveness of MBIs 
for improving psychological, operational, and quality of life outcomes (Linda E. Carlson, 
2012; Yaowarat Matchim, Armer, & Stewart, 2011). 
With strong self-reported evidence that mindfulness meditation is effective for 
alleviating some symptoms commonly experienced by cancer patients, but an incomplete 
understanding of the underlying process, further research is needed using objective 
outcome measures that also have potential to provide clues to bodily mechanisms. 
Salivary cortisol is one such measure that has been used increasingly in recent research. 
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2.3 Diurnal Cortisol and HPA axis regulation 
Cortisol is the primary human glucocorticoid and is an essential steroid hormone 
produced in the body as an end product of the HPA axis. Its production is stimulated 
beginning in the hypothalamus which releases corticotrophin releasing hormone (CRH) in 
response to a range of biological and environmental mediators including both physical 
and psychological stress (Levine, Zagoory-Sharon, Feldman, Lewis, & Weller, 2007). CRH 
functions to stimulate the release of adrenocorticotropic hormone (ACHT) from the 
pituitary gland, which in turn acts on the adrenal cortex to produce cortisol. Cortisol 
functions broadly in the body by suppressing non-essential function of the immune, 
reproductive, and digestive systems and acting to prepare the body for action by 
increasing blood pressure, releasing stored energy sources for use, and acting as a 
powerful anti-inflammatory (Levine et al., 2007). Its flux in the body is affected by 
environmental stimuli, circadian rhythms, and sleep cycles (Levine et al., 2007). 
Additionally, as part of a negative feedback loop, cortisol acts as an inhibitor to the HPA 
axis, suppressing the release of CRH and ACHT. Dysregulation of the HPA axis and its 
components, including irregular cortisol levels and patterns have been associated with a 
range of adverse outcomes including reduced cancer survival (L. Cohen et al., 2012; 
Schrepf et al., 2015; Sephton et al., 2013, 2000) depression (Poole et al., 2016), psychiatric 
illness (de Kloet, Joëls, & Holsboer, 2005), cardiovascular events and mortality (Kumari, 
Shipley, Stafford, & Kivimaki, 2011) and chronic fatigue (Powell, Liossi, Moss-Morris, & 
Schlotz, 2013). Over the past two decades, free cortisol levels have notably been used as 
a biological indicator of stress and as a surrogate for HPA axis function (Kirschbaum & 
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Hellhammer, 1994). This has been facilitated by the ease of collection of salivary cortisol 
measures as an economic, non-invasive, and reliable measure of free blood serum cortisol 
that can be performed without the assistance of medical personnel and in a variety of 
environments (Hellhammer, Wüst, & Kudielka, 2009). 
More recently, and primarily with the use of salivary cortisol measures rather than 
blood or urinary cortisol, methods have been trending towards measures of diurnal 
cortisol rhythm as opposed to total cortisol over a 12 or 24-hour period. Research 
suggests that the rhythm of cortisol levels during the day may be relevant to disease 
status and prognosis (Adam & Kumari, 2009). Typically, the diurnal cortisol rhythm 
measured immediately upon awakening begins relatively high with a spike (50-60% 
increase) within the first 30 to 45 minutes after waking followed by a more gradual decline 
over the rest of the day to a low point around midnight with established differences 
between men and women (Adam & Kumari, 2009; Pruessner et al., 1997). This typical 
daily rhythm has been observed as a consistent pattern in healthy individuals and 
deviations are associated with dysregulation of the HPA axis function through both 
environmental influence and disease (Stone et al., 2001). 
Although the use of salivary cortisol to measure diurnal rhythm has gained 
popularity, methodology for collecting and analyzing cortisol samples remain 
inconsistent. A recent review of RCTs by Ryan and colleagues resulted in a series of 
recommendations for improving methodology and consistency across studies for the use 
of salivary cortisol as an indicator of HPA axis function (Ryan, Booth, Spathis, Mollart, & 
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Clow, 2016). Ryan and colleagues suggested collecting two days of cortisol samples for 
each assessment period due to intra-individual variation between days, a 
recommendation that was also made by Clow and colleagues to allow for the assessment 
of participant adherence (Clow, Thorn, Evans, & Hucklebridge, 2004). Ryan and colleagues 
also recommend collecting enough salivary samples each sample day to develop a full 
picture of cortisol rhythm (Ryan et al., 2016). Practically, this included collecting a series 
of at least two samples beginning with awakening time up to 30-45-minute post 
awakening in order to assess the cortisol awakening response (CAR) which is the typical 
spike in cortisol post awakening. Additionally, they suggested a least one evening sample 
to allow for assessment of total daily cortisol secretion, and to determine the diurnal 
change in cortisol levels from awakening to evening (generally negative in healthy 
individuals) (Ryan et al., 2016). 
Along with methodological inconsistencies in the sampling of cortisol, 
interpretation of resulting cortisol values varies across studies. In part, this is due to the 
broad function and cyclical nature of cortisol in the body but also due to differences in 
cortisol patterns between populations (i.e. men and women or youth and adults) and a 
limited understanding of clinical significance. Particularly for absolute measures of total 
diurnal cortisol, but also for the CAR, both depressed and heightened cortisol levels 
(hypo- and hyper-cortisolism) have been associated with adverse physical and 
psychological conditions (Chida & Steptoe, 2009; Heim, Ehlert, & Hellhammer, 2000). 
Fries and colleagues concluded based on animal models that hypocortisolism may be a 
reaction to hyperactivity of the HPA axis from chronic stress and suggested several 
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possible biological mechanisms (Fries, Hesse, Hellhammer, & Hellhammer, 2005). This 
idea matches with explanations of allostatic overload. Essentially, although an acute 
stress response adaptively prepares the body for ‘fight-or-flight’, sustained or chronic 
stress can trigger allostatic overload, an inability of the body to effectively regulate stress 
response, which can contribute to bodily deterioration (as in the case of chronically high 
blood pressure) and exhausts the capability of the HPA axis to react appropriately to 
environmental cues (McEwen, 2008). Heim and colleagues speculated with 
hypocortisolism, the reduced ability to respond to stressful stimuli could underlie 
vulnerability to some stress related diseases (Heim et al., 2000). Furthermore, in a 2009 
review, Chida and Steptoe examined associations of various psychosocial factors with the 
CAR and found that a heightened or depressed CAR is associated with different factors 
(Chida & Steptoe, 2009). Specifically, they found that heightened CAR was significantly 
associated with job stress and general life stress and that depressed CAR was significantly 
associated with fatigue, burnout, or exhaustion; suggesting a link between chronic stress 
and reduced CAR (Chida & Steptoe, 2009). Chida and Steptoe also proposed that their 
failure to find an association between CAR and depression may have been because 
depression has been associated with both heightened and reduced CAR; depending on 
the intensity of the depressive episode (Chida & Steptoe, 2009). Because dysregulation of 
the HPA axis leading to either elevated or depressed cortisol levels is thought to be 
detrimental, interpreting the CAR and total daily cortisol is not straightforward. 
Researchers have used various strategies to model a normalizing effect of mindfulness 
interventions or cortisol levels. Bränström and colleagues examined how segmenting by 
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tertiles of cortisol levels at baseline predicted change in cortisol levels (Bränström, 
Kvillemo, & \AAkerstedt, 2013), and Carlson and colleagues divided the baseline sample 
into ‘high’ and ‘low’ cortisol groups, and found that those with low cortisol tended to 
show increased levels post intervention and those with ‘high’ cortisol tended to show 
decreased levels post intervention (Linda E Carlson, Speca, Patel, & Goodey, 2004). There 
has been a discussion in the literature of identification of standard normative cortisol 
values (Clow et al., 2004; Heim et al., 2000), and a recent publication using cortisol from 
a sample of over 18,000 healthy participants has supplied operational reference ranges 
for salivary cortisol across the day by age categories for both men and women (see Table 
2.2 for an excerpt) (R. Miller et al., 2016). These normative ranges have potential to be 
used in identifying both hypocortisolism and hypercortisolism in diseased populations 
where supplied reference age groups and sample times are relevant to the comparison 
population and sampling procedure. 
Table 2.2 Reference values from 50th percentiles of salivary cortisol concentrations at 
various hours after 07:00 (excerpted from R. Miller et al., 2016) 
 
Age Sex 1 h 3.5 h 6 h 8.5 h 11 h 13.5 h 16 h 
31-40 F 6.5 3.6 2.1 1.4 1.0 0.7 0.6 
31-40 M 6.6 3.6 2.1 1.4 1.0 0.7 0.6 
41-50 F 6.3 3.4 2.0 1.3 0.9 0.7 0.6 
41-50 M 6.3 3.4 2.0 1.3 0.9 0.7 0.6 
51-60 F 6.4 3.5 2.0 1.3 0.9 0.7 0.6 
51-60 M 7.1 3.9 2.3 1.5 1.0 0.8 0.7 
61-70 F 6.8 3.7 2.2 1.4 1.0 0.8 0.6 
61-70 M 7.3 4.0 2.3 1.5 1.1 0.8 0.7 
71-80 F 7.2 3.9 2.3 1.5 1.1 0.8 0.7 
71-80 M 7.9 4.3 2.5 1.6 1.2 0.9 0.7 
Note. All concentrations are scaled in nmol/L. Abbreviations in the sex column: F = 
female (grey shaded cells), M = male. 
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In comparison to assessing CAR and total diurnal cortisol secretion, interpretation 
of the change in cortisol from awakening (or peak level) to evening (often assessed using 
diurnal cortisol slope) is relatively direct. Research has shown that little or no decrease 
over the day in cortisol levels as compared to a steeper decline in cortisol levels is an 
indicator of HPA axis dysregulation (Adam & Kumari, 2009). 
2.4 Current Literature 
There has been a proliferation of papers assessing mindfulness based 
interventions in cancer care in the past decade, and particularly since 2010. The majority 
have focused on self-reported symptomology such as psychological wellbeing, stress, and 
fatigue. Current evidence from systematic reviews of RCTs provides strong evidences that 
use of mindfulness interventions in cancer patients is effective for improving 
psychological and quality of life outcomes such as mood, distress, and other psychosocial 
outcomes (Linda E. Carlson, 2012). The evidence of impact of mindfulness interventions 
in cancer survivors on HPA axis function through assessment of cortisol level is less 
concrete. Four relatively recent original pre-post or non-randomized controlled clinical 
trials have been conducted which measured salivary cortisol as an outcome variable 
(Lengacher et al., 2012; Y. Matchim, Armer, & Stewart, 2011; Matousek, Pruessner, & 
Dobkin, 2011; Witek-Janusek et al., 2008). Matchim and colleagues (2011) conducted a 
quasi-experimental design study by comparing a group of 19 breast cancer survivors in 
one city who participated in an 8-week MBSR class to a group of 17 survivors in a nearby 
city who did not receive the MBSR intervention (Y. Matchim et al., 2011). For financial 
reasons, cortisol was not measured in all participants; 10-12 randomly selected 
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individuals from each group provided two cortisol samples over a one-day period, one at 
awakening and another at 4:00pm. The same individuals provided cortisol samples 
immediately after conclusion of the 8-week MBSR program and 1-month post conclusion. 
Matchim and colleagues compared the morning and evening samples separately within 
and between groups and found a significant decrease of 0.22 µg/dl in the morning 
cortisol measurement from baseline to directly after the MBSR intervention for the 
intervention group, but not the control (Y. Matchim et al., 2011). No other significant 
changes were noted in cortisol. The study also found statistically significant reduction in 
diastolic blood pressure and increased mindfulness in the intervention arm at 1 month 
follow-up compared to baseline levels (Y. Matchim et al., 2011). Compared to the control 
group, heart rate, respiratory rate, and systolic blood pressure were significantly lower 
and mindfulness was significantly higher in the intervention arm at 1 month follow-up (Y. 
Matchim et al., 2011). Matousek and colleagues similarly assessed cortisol in a population 
of 33 all-female breast cancer survivors (Matousek et al., 2011). Their outcome of interest 
was the CAR, thus only morning salivary cortisol was collected. Salivary samples were self-
administered at awakening, and at 30- and 45-minute post awakening for three 
consecutive days both before and after the 8-week MBSR intervention (Matousek et al., 
2011). In their analysis, Matousek and colleagues found the CAR to be stable across the 
three days sampled at baseline and post intervention, and that CAR increased significantly 
post intervention compared to baseline, mostly due to sustained awakening response at 
the 45 minute sampling point (Matousek et al., 2011). Their results contrasted with 
another study assessing impact of MBSR on CAR in substance abuse patients by Marcus 
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and colleagues (2003) which found CAR was significantly reduced post intervention rather 
than increased (Marcus et al., 2003). They attributed this reversal of effect to the initial 
depressed CAR response in their cancer population compared to normative values 
advanced by Wust and colleagues (2000), a conclusion in line with the idea that chronic 
stress can lead to lowered reactivity of the HPA axis (Wust et al., 2000). Witek-Janusek 
and colleagues compared 75 women with early stage breast cancer, scheduled to receive 
radiation, but not chemotherapy treatment between self-selected control and 
intervention groups to a healthy cancer-free group of age matched women (Witek-
Janusek et al., 2008). The intervention consisted of an 8-week MBSR program modelled 
after the original Kabat-Zinn 1990 program (Witek-Janusek et al., 2008). Evening blood 
plasma cortisol was collected from a portion of the cancer-control and intervention 
groups (only for women who were available to have their blood drawn from 4-6pm) at 
baseline, mid-intervention, directly post intervention, and 1 month after the conclusion 
of the intervention (Witek-Janusek et al., 2008). In comparison to the cancer-free group, 
both the cancer-control and intervention groups had significantly higher cortisol at all 
time points (Witek-Janusek et al., 2008). The intervention group had significantly lower 
evening plasma cortisol levels at completion of the MBSR program compared to the 
cancer-control group (Witek-Janusek et al., 2008). Lengacher and colleagues included 
both advanced stage cancer patients and their caregivers in a 2012 study; but for the sake 
of relevancy, only the cortisol response in patients will be discussed here (Lengacher et 
al., 2012). Breast, colon, lung, and prostate cancer patients were recruited who had 
completed surgery and were receiving radiation and/or chemotherapy (Lengacher et al., 
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2012). The intervention was a modified MBSR program for cancer patients, that was 
reduced to 6-weeks (compared to the standard 8-weeks) and 3 of the 6 sessions were 
self-directed with the assistance of audiotapes (Lengacher et al., 2012). Patients provided 
a saliva sample directly before and after the first (n=10), third (n=8), and sixth (n=7) MBSR 
class (which were in-person and held from 10:00am to 12:00pm). Lengacher and 
colleagues found significantly reduced cortisol for patients post MBSR class compared to 
pre MBSR class at the first and third class, but not at the sixth (Lengacher et al., 2012). 
Cortisol levels were significantly reduced between baseline at the first class and baseline 
at the sixth class. They did not specifically address confounding by time in cortisol 
sampling. It would be expected in a healthy diurnal cortisol rhythm for cortisol levels to 
decline between the hours of 10:00am and 12:00pm in the absence of any situational 
stress response regardless of participation in a mindfulness program. The authors did 
concede that lack of a control group disallowed contribution of cortisol reduction 
exclusively to the MBSR for cancer patients intervention (Lengacher et al., 2012). 
Some consistencies and inconsistencies can be seen from this brief review of the 
most recent original pre-post and non-randomized controlled clinical trials of mindfulness 
meditation including cortisol as an outcome measure in cancer patients and survivors. 
Participants were mostly female breast cancer patients, and salivary cortisol was primarily 
used as the outcome measure (with the exception of the Witek-Janusek study, which used 
free plasma cortisol) (Witek-Janusek et al., 2008). Sampling procedures for cortisol vary 
widely between these four studies, from a single evening time point at each follow up by 
Witek-Janusek and colleagues (Witek-Janusek et al., 2008), to three repeated days 
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including three morning samples each day to assesses CAR at each follow-up time by 
Matousek and colleagues (Matousek et al., 2011). None assessed total diurnal cortisol, 
more than one summary measure for cortisol, or diurnal cortisol decline, although 
Matchim and colleagues (2011) had the potential to assess diurnal cortisol decline from 
collections of both awakening and evening samples (Y. Matchim et al., 2011). These 
studies primarily used a full 8-week MBSR course as the intervention, with the exception 
of the Lengacher study (2012) which used a shortened program of 6 weeks that included 
a self-directed portion (Lengacher et al., 2012). Witek-Janusek and colleagues (2008) and 
Lengacher and colleagues, (2012) included patients actively receiving treatment for 
cancer rather than post treatment patients (Lengacher et al., 2012; Witek-Janusek et al., 
2008). Results from the four studies, although based on various cortisol measurements, 
were consistently interpreted as suggesting a beneficial effect of mindfulness 
interventions on cortisol levels. The Matchim study reported decreased awakening 
cortisol levels post intervention (Y. Matchim et al., 2011), Matousek reported increased 
CAR post intervention (Matousek et al., 2011), Lengacher reported decreased cortisol 
after the first and third mindfulness classes (compared to the pre-class measure) and 
decreased cortisol from the first class to the sixth class (Lengacher et al., 2012), and 
Witek-Janusek reported decreased evening cortisol levels post intervention compared to 
a non-randomized control group (Witek-Janusek et al., 2008). Although varied, all 
significant changes in cortisol post intervention were construed to be positive indicators 
of improved HPA axis functioning. 
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Only three RCTs of a mindfulness intervention in cancer patients using cortisol as 
a measure of HPA axis function have been conducted to date: Bränström and colleagues, 
(2013); Carlson and colleagues, (2013); and Lipschitz and colleagues, (2013) (Bränström 
et al., 2013; L. E. Carlson et al., 2013; Lipschitz, Kuhn, Kinney, Donaldson, & Nakamura, 
2013). Bränström and colleagues randomized 71 total cancer patients (70 females, 1 
male) of various diagnoses, but not currently undergoing treatment to an 8-week MBSR 
program or a waitlist control (Bränström et al., 2013). A single self-administered 
awakening cortisol sample was collected from each participant at baseline, 3 months from 
baseline, and 6 months from baseline. Participants were 93% compliant with cortisol 
reporting. Results for self-reported measures were described in a separate publication 
(Bränström, Kvillemo, Brandberg, & Moskowitz, 2010), but briefly, they found significant 
differences between the intervention and control arms in perceived stress, positive states 
of mind, and post-traumatic avoidance symptoms at the 3 month follow-up, but not at 
the 6 month follow-up. In their 2013 publication of cortisol outcomes, Bränström and 
colleagues failed to find overall effects of the intervention on cortisol levels at the 3-
month or 6-month follow-up, but did find significant effect modification by baseline 
cortisol levels in the intervention group at the 3-month follow-up (Bränström et al., 2013). 
Participants in the intervention group with initially low cortisol levels (defined as the 
lower tertile for the study population) at baseline saw an increase in cortisol on average, 
and participants with initially high cortisol levels (defined as the upper tertile for the study 
population) saw a decrease in cortisol on average compared to the control group. The 
effect modification observed by baseline levels was not sustained at 6-month follow-up. 
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They suggest that this normalization of baseline cortisol levels observed at the 3 month 
follow-up may not have been sustained at the 6-month follow-up due to a lack of 
continued mindfulness meditation practice by most participants, and acknowledge the 
use of a single awakening cortisol measurement and small sample size as limitations to 
their study (Bränström et al., 2013). The largest RCT to date was conducted by Carlson 
and colleagues (2013) (L. E. Carlson et al., 2013) comparing impact of a Mindfulness Based 
Cancer Recovery (MBCR) intervention and a Supportive-Expressive Group Therapy (SET) 
program to a single-day stress management control program. MBCR is adapted from 
traditional MBSR to be used specifically in a cancer population and closely follows the 
original MBSR program. MBCR and SET are similar in functional characteristics such as 
total contact hours, group format, and structure, however SET highlights emotional 
expression and group support while MBCR is focused on mindfulness meditation and daily 
mindful awareness. Two hundred and seventy-one female breast cancer survivors who 
qualified as distressed by scoring above a predetermined cutoff on an indicator of distress 
were randomly assigned in a 2:2:1 ratio to the MBCR, SET, or a minimal treatment control 
group. Salivary cortisol was measured 4 times per day over 3 consecutive days at 30-
minute post awakening, 12:00pm, 5:00pm, and bedtime at baseline and intervention 
completion at 8 weeks (L. E. Carlson et al., 2013). Diurnal cortisol slope for each individual 
was calculated using all 12 samples from the 3-day period at baseline and post-
intervention (L. E. Carlson et al., 2013). They found that the steepness of the diurnal 
cortisol slope was maintained in both the MBCR and SET groups baseline to post-
intervention, while the slope for the control group became flatter, indicating that both 
24 
interventions may have a protective effect against progressive HPA axis dysregulation (L. 
E. Carlson et al., 2013). Although this is the largest RCT assessing effect of a mindfulness 
intervention on cortisol levels in a cancer population, the study had a high attrition rate 
(roughly 30% for each group), no long-term follow-up, and included only female breast 
cancer survivors (L. E. Carlson et al., 2013). In their 2013 paper, Lipschitz and colleagues 
(2013) focused primarily on sleep regulation, but measured salivary cortisol as an 
outcome variable assessing a mindfulness intervention (Lipschitz et al., 2013). Fifty-seven 
male and female cancer survivors in remission for greater than 3 months and reporting 
sleep disturbance were randomized to either a Sleep Hygiene Education (SHE) standard 
care group (n=18), a Mind-Body Bridging (MBB) intervention program (n=19) or a 
Mindfulness Meditation (MM) intervention program (n=20) (Lipschitz et al., 2013). The 
SHE program was an information session about dealing with sleep disturbances, the MBB 
program was centered on teaching awareness of dysfunctional thought processes and 
identifying sources of sleep problems, and the MM program was a 3-week modification 
of a traditional MBSR program that focused on mindfulness meditation skills. Cortisol was 
sampled at baseline prior to the intervention and within one-week post intervention 
(Lipschitz et al., 2013). At each follow-up, cortisol was sampled on two consecutive days: 
the first day at 30-minute post awakening, noon, afternoon (5:00pm), and bedtime; the 
second day at awakening. Having the first sample on the first day be collected 30-minute 
post awakening was employed to increase compliance, but prevented examination of the 
CAR as a response measure. In their analysis, they included awakening sample alone as 
an outcome variable but also examined total diurnal cortisol using an area under the 
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curve summary measure and mean diurnal profile using the 4 samples collected on the 
same day as outcome variables. No significant effects on salivary cortisol were found for 
the mindfulness intervention in comparison to either the MBB intervention or SHE control 
(Lipschitz et al., 2013). They found no significant differences in awakening cortisol post 
MM or MBB intervention compared to the SHE control group, although the SHE group did 
show a decline post intervention (p=0.052) (Lipschitz et al., 2013). Models of total diurnal 
cortisol and mean diurnal profile showed no significant difference between the three 
groups post intervention when controlling for baseline levels (Lipschitz et al., 2013). There 
was a significant decrease in self-reported sleep problems for the MM and MBB 
interventions compared to the SHE control group (Lipschitz et al., 2013). 
Similar to the non-randomized clinical trials of mindfulness interventions in cancer 
survivors, the three RCT studies have varied methodological approaches and different 
sampling procedures for cortisol and thus examined different outcome variables. Only 
Lipschitz and colleagues (2013) (Lipschitz et al., 2013) included a relevant sample of both 
male and female survivors although there was 1 male participant in the Bränström study 
(Bränström et al., 2013). Bränström and colleagues (Bränström et al., 2013) also was the 
only study to include a longer-term follow-up on cortisol post-intervention whereas 
Carlson (2013) and Lipschitz (2013) only assessed cortisol directly post intervention (L. E. 
Carlson et al., 2013; Lipschitz et al., 2013) although Carlson and colleagues did conduct a 
longer-term follow-up on self-report measures from the same study (Linda E. Carlson et 
al., 2016). The Lipschitz study was the only study to evaluate an abbreviated mindfulness 
program: 3-weeks compared to standard 8-week (Lipschitz et al., 2013). None of the three 
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studies collected cortisol measures that would allow for the calculation of CAR as an 
outcome variable, although one did use diurnal cortisol slope (without an awakening 
anchor sample) as an outcome measure (L. E. Carlson et al., 2013). Two specifically 
enrolled only distressed cancer survivors – identified from a distress scale or from self-
reported sleep dysregulation, and these two also compared the mindfulness intervention 
to another active intervention group and a minimal-treatment control group (L. E. Carlson 
et al., 2013; Lipschitz et al., 2013). The Carlson (2013) study was the largest trial to date, 
with 271 participants, the others including only up to 71 participants (L. E. Carlson et al., 
2013). Importantly, outcomes were also varied. Lipschitz and colleagues found no 
significant effects of the intervention on cortisol levels (Lipschitz et al., 2013) although 
this could potentially be explained by their use of cortisol averages rather than 
investigating effect modification by levels of baseline cortisol, and because they did not 
examine diurnal rhythm parameters. Relevant to this rationale, Bränström and colleagues 
found no overall effect of the mindfulness intervention on cortisol at the 3- and 6-month 
follow-up but did observe normalization of awakening cortisol levels at the 3-month 
follow-up in the treatment group (Bränström et al., 2013).  Those with high baseline 
cortisol values tended to show decreases and those with low baseline cortisol values 
tended to show increases (Bränström et al., 2013). Finally, Carlson and colleagues (2013) 
found that diurnal cortisol slope was maintained in the mindfulness intervention group, 
but became flatter in the control group and that bedtime cortisol levels decreased in the 
mindfulness group relative to the control (L. E. Carlson et al., 2013). 
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With this broad range of study methodologies, measurement protocols for 
cortisol, and cortisol outcome variables examined, it is not surprising that there is a lack 
of a firm consensus in the literature concerning effectiveness of mindfulness 
interventions as evaluated by RCTs on the objective marker of HPA axis functioning, 
cortisol. Our study has potential to add to this growing literature stream through various 
methodological and analytical strengths. First, we are assessing an abbreviated 
mindfulness intervention similar to that employed by Lipschitz (ours is 4-weeks versus 
their 3-week intervention) and examine in our population both significant outcomes from 
the Carlson and Bränström studies that were not examined in the Lipschits study: 
modification by baseline cortisol level and diurnal cortisol decline (Bränström et al., 2013; 
L. E. Carlson et al., 2013; Lipschitz et al., 2013). Evaluation of abbreviated mindfulness 
programs was encouraged in a 2015 review by Rouleau and colleagues to improve 
program accessibility if lower ‘doses’ of mindfulness training are shown to be equally 
effective (Linda E. Carlson, 2012) and a 2016 review by Ryan and colleagues 
recommended examining three cortisol outcome measures: total diurnal cortisol 
(typically calculated as area under the curve), CAR, and diurnal cortisol decline (typically 
assessed as diurnal slope) (Ryan et al., 2016). Additionally, using a model that allows 
examination of a normalizing effect of the intervention is based on results from two 
studies showing regulation of both high and low baseline cortisol after mindfulness 
interventions (Bränström et al., 2013; Linda E Carlson et al., 2004) and biological 
indications concerning HPA axis regulation of acute and chronic stress. Furthermore, this 
study also includes both male and female cancer patients, high subject retention, and a 
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longer-term follow-up at 3 months (i.e. 2-month post-intervention); elements that are 
lacking in the current literature.
29 
Chapter 3: Method
3.1 Study Design 
Study Population 
Two cohorts selected from Greenville Health Systems (GHS) of cancer patients 
living in and around Greenville SC, aged greater than 18 years old were identified from 
clinical records or GHS providers and contacted to determine interest. Trial for the first 
cohort was conducted beginning in November of 2015 and included 20 total participants 
randomly assigned to the intervention (n=10) or the control arm (n=10). The second 
cohort was conducted beginning in January of 2016 and included 18 total participants 
randomly assigned to the intervention (n=10) or the control arm (n=8). A total of 36 
participants were followed to completion of the study. Two participants were lost to 
follow-up. Participants were incentivized with a 50-dollar gift card at follow-up. 
Inclusion and Exclusion Criteria 
Recruited participants were cancer survivors 18 years or older, capable of 
participating in the intervention classes and providing their own transportation to class, 
and able to read, write, and speak in English. Participants were excluded if they had 
previous experience or training in MBSR or were taking corticosteroid therapy equal to or 
greater than prednisone 25mg/day. 
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Intervention Arm Mindfulness Program 
Four weekly meetings of 2.5 hours each for a CMCS class adapted from the original 
8-week MBSR program designed by Jon Kabat-Zinn (Kabat-Zinn, 1990). All mindfulness 
sessions were facilitated by a Licensed Independent Social Worker – Clinical Practice 
(LISW-CP) with Oncology Social Work Certification (OSW-C) and included introductory 
meditation practices focusing on attention regulation, body and thought awareness, and 
emotional control. The twenty participants randomized to the intervention arm had a 
95% attendance rate to the 4 CMCS classes. 
Control Arm Breathing Course 
The control program consisted of a single 30-minute breathing exercise presented 
to only the control group at week 1 after baseline assessment. Topics included the relaxed 
breath exercise (4-7-8 count breathing) and breath counting. 
3.2  Measurements 
Cortisol 
Salivary cortisol samples were collected on one day at baseline and at each follow-
up day (6 weeks and 3 months). Collection was self-administered using Salivette® 
(Sarstedt AG & Co, Germany) saliva collection kits which provide chewable roll-shaped 
synthetic saliva collectors that once chewed until saturation are replaced in the sample 
tube. The date and time of collection were written on the tube. Participants provided 
samples and recorded timing of cortisol measurements six times on each sample day; at 
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awakening, 15-minute, 30-minute, and 45-minute post awakening, and before their 
evening meal, and before sleeping. Samples were returned to the laboratory in a pre-paid 
envelope and transit time was recorded. From the samples, salivary cortisol was assessed 
and reported in nmol/L. Over the three time periods for all participants, compliance with 
supplying cortisol samples was 97%. 
Questionnaires 
Self-administered questionnaires were filled out by participants at each time 
point. Participant compliance with returning questionnaires was 100%. The 
questionnaires surveyed participants about the following information: 
Demographic Information 
Self-reported age, gender, race, marital status, education level, height and weight, 
employment status, and tobacco and alcohol use and frequency. 
Mindful Attention Awareness Scale (MAAS) 
The MAAS is a survey designed to assess individual differences in attention and 
regularity of mindfulness. It consists of 15 statements concerning some episode indicating 
lack of present awareness (e.g. “I do jobs or tasks automatically, without being aware of 
what I’m doing” or “I forget a person’s name almost as soon as I’ve been told it for the 
first time”). Participants indicate the frequency of the item over the past 1 month on a 
scale of 1-6 (“almost always” through “almost never”), a higher average score indicates 
higher mindfulness (Brown & Ryan, 2003). The MAAS scale was developed and validated 
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in a nonclinical population in 2003 and has since been assessed for construct validity in a 
cancer population (Linda E. Carlson & Brown, 2005). 
Pittsburgh Sleep Quality Index (PSQI) 
The PSQI is a 19 item questionnaire relating to sleep quality and disturbances over 
the past 1-month interval (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). Participants 
respond to statements (e.g. “Cannot get to sleep within 30 minutes”, “Feel too hot”) by 
indicating frequency on a scale of 1-4 (“Not within the past month” up to “Three or more 
times a week”). Seven component scores of 0-3 are developed from raw scores to 
separately assess sleep quality, latency, duration, efficiency, disturbances, medication, 
and daytime function. A global sleep quality score is generated by summing the 7 
component scores for an overall range of 0-21. In non-clinical populations, a global sleep 
quality score above 5 is used to identify poor sleep patterns, however Beck and colleagues 
suggested that in clinical populations, such as cancer patients, a cutoff of 8 may be more 
appropriate to categorize poor sleepers (Beck, Schwartz, Towsley, Dudley, & Barsevick, 
2004). This questionnaire has been validated and assessed for reliability as well as 
determined to have construct validity in a cancer population (Beck et al., 2004). 
Center for Epidemiologic Studies Depression Scale (CES-D) 
The CES-D is a validated 20 item self-report questionnaire to assess depressive 
symptomatology in the general population (Radloff, 1977). Participants indicate 
frequency within the last week in response to statements including “I felt that everything 
I did was an effort” or “I enjoyed life”. Each item is scored from 0-3 with higher scores 
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indicating higher frequency of depressive symptoms or lower frequency of positive 
feelings. A final score is calculated as the sum of all indicators (range 0-60) with 16 or 
greater indicating depression. 
Perceived Stress Scale (PSS-10) 
The PSS is a 10-item questionnaire asking participants to indicate frequency within 
the last month of common thoughts and feelings related to stress (e.g. “In the last month 
how often have you been angered because of things that were outside of your control?”). 
Participants rate each item on a scale of 0-4 (“Never” through “Very Often”) and items 
are summed for a possible overall score between 0 and 40; with higher scores indicating 
higher perceived stress (S. Cohen, Kamarck, & Mermelstein, 1983). The PSS-10 has been 
validated in an older adult population, and higher scores are associated with higher levels 
of anxiety, depression, and negative affect (Ezzati et al., 2014). 
Daily Stress Inventory (DSI) 
The DSI is a self-report questionnaire asking participants to rate their stress 
response to 58 life situations (e.g. “Waited longer than you wanted” and “Heard some 
bad news”) if they occurred within the last 24 hours on a scale of 1-7 (“Occurred but was 
not stressful” to “Caused me to panic”). Three summary measures are typically calculated: 
number of events, sum of impact, and average impact per event. The DSI has been 
validated, and has shown value as a predictor of occurrence of some symptoms of chronic 
illness (Brantley & Jeffries, n.d.). 
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Rapid Assessment of Physical Activity (RAPA) 
The RAPA is a 9-item questionnaire that serves as an easy-to-administer measure 
of physical activity for use in clinical settings. The first 7 questions assess aerobic physical 
activity and combine to categorize individuals as ‘sedentary’ ‘under-active’ ‘under-active 
regular light’ ‘under-active regular’ and ‘active’. The final two questions combine to 
provide a strength and flexibility score ranging from 0 to 3, with 3 suggesting higher 
participation in activities that promote strength and flexibility. The English version of 
RAPA has been validated for use among older adults (Topolski et al., 2006). 
Additional Measures 
Additional information not used in this study also was collected; including 
nutritional information, caffeine intake, fruit and vegetable consumption, as well as blood 
samples and actigraph data. 
3.3 Model Variables 
Outcome Variables 
Diurnal cortisol decline (𝐃𝐂𝐃): DCD is calculated as the awakening cortisol 
measurement subtracted from the average of the evening and bedtime cortisol 
measurement values for each patient. From the following equation, 𝐷𝐶𝐷𝑝,𝑑 is change in 
cortisol from measurement point 𝑚1 to the average of measurement points 𝑚5 and 𝑚6 
for each patient 𝑝 on follow-up day 𝑑. 
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𝐷𝐶𝐷𝑝,𝑑 =  (
𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝑝𝑑5 + 𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝑝𝑑6
2
) − 𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝑝𝑑1 
Cortisol values representing the CAR (i.e. those collected at 15-, 30-, and 45-
minute post awakening) are not included in the regression line to calculate diurnal cortisol 
decline for two primary reasons. First, the CAR is thought to be regulated by a mechanism 
distinct from other cortisol rhythms (Clow et al., 2004). Clow and colleagues proposed 
that the CAR is regulated by the hypothalamic suprachiasmatic nucleus and indicated that 
it is affected by light upon awakening – low light leading to higher CAR response (Clow et 
al., 2004). For this reason, including immediate post-awakening measurements could bias 
estimates of diurnal cortisol decline. Additionally, in trials where clinical outcomes were 
indicated with flatter diurnal cortisol slopes (smaller diurnal decline), only the awakening 
and evening cortisol measurements were included in analysis (Poole et al., 2016; Sephton 
et al., 2013, 2000). 
Change in DCD (∆𝐃𝐂𝐃𝐩
𝟏 and ∆𝐃𝐂𝐃𝐩
𝟐): Difference between DCD at baseline (0) and 
follow-up one (1) and baseline and follow-up two (2) respectively for each patient 𝑝. 
∆𝐷𝐶𝐷𝑝
1 = (𝐷𝐶𝐷𝑝1 − 𝐷𝐶𝐷𝑝0) 
∆𝐷𝐶𝐷𝑝
2 = (𝐷𝐶𝐷𝑝2 − 𝐷𝐶𝐷𝑝0) 
Change in cortisol level (∆𝐂𝐩,𝐦
𝟏  and ∆𝐂𝐩,𝐦
𝟐 ): Difference in cortisol level between 
baseline (0) and follow-up one (1) and baseline and follow-up two (2) respectively for each 
patient 𝑝, and cortisol measurement point 𝑚. 
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∆𝐶𝑝,𝑚
1 = 𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝑝1𝑚 − 𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝑝0𝑚 
∆𝐶𝑝,𝑚
2 = 𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝑝2𝑚 − 𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙𝑝0𝑚 
 
Exposure Variable 
Randomization to the intervention mindfulness program or to the control 
breathing course was the primary exposure of interest. 
Confounders 
Potential confounders that were assessed for impact on the ability of the model 
to predict changes in diurnal cortisol patterns: sex, age, race, perceived stress, physical 
activity level, depression, sleep quality, and cohort (Adam & Kumari, 2009; R. Miller et al., 
2016). 
Effect Modifiers 
Baseline levels of cortisol were examined as a potential effect modifier (Bränström 
et al., 2013). 
3.4 Statistical Analysis 
We performed three distinct analyses. First, a baseline analysis to assess 
association between DCD and variables of interest in the sample population. Second, we 
investigated the effect of the treatment on change in DCD and third, we investigated the 
effect of the treatment on cortisol level changes for each cortisol measurement. 
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Baseline Analysis 
Baseline DCD can be calculated using the method explained in Subsection 3.3 
using baseline day (𝑑 = 0). We examine the crude and multivariable association between 
DCD at baseline and measured variables of interest including depression, sex, perceived 
stress, age, sleep quality, physical activity, and cohort when indicated by a crude 
association. Refer to Subsection 1.2 specific aim 1 for hypothesized associations. 
DCD𝑝,𝑑=0 = 𝛽0 +  𝛽1𝑑𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 + 𝛽2𝑠𝑒𝑥 + 𝛽3𝑠𝑡𝑟𝑒𝑠𝑠 + 𝛽4𝑎𝑔𝑒 + 𝛽5𝑠𝑙𝑒𝑒𝑝 + 𝛽6𝑃𝐴
+ 𝛽7𝑐𝑜ℎ𝑜𝑟𝑡 + 𝜀𝑝0 
Analysis on ∆𝐃𝐂𝐃 
∆DCD for each patient is calculated as explained in Subsection 3.3. We use the 
following regression model in order to understand the effect of treatment (𝑡𝑟) when 
controlling for sex, age, and other potential confounders (listed in Subsection 3.3): 
∆DCD𝑃 = 𝛽0 +  𝛽1𝑡𝑟 + 𝛽2𝑠𝑒𝑥 + 𝛽3𝑎𝑔𝑒+. . . +𝜀𝑝 
We expect 𝛽1 to be significantly less than 0 in accordance with specific aim 2 in 
Subsection 1.2. 
Analysis on change in cortisol level (∆𝐂𝐩,𝐦
𝟏  and ∆𝐂𝐩,𝐦
𝟐 ) 
We used change in each cortisol measurement for each patient, ∆𝐶𝑝,𝑚
1  and ∆𝐶𝑝,𝑚
2  
(as explained in Subsection 3.3) as the dependent variable in our linear regression models. 
This results in 12 total models of change in cortisol (6 for each cortisol measure by 2 for 
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each follow-up day comparison). Since research indicates that both hypercortisolism and 
hypocortisolism are related to HPA axis dysregulation and that cancer survivors may have 
dysregulated HPA axis function (Abercrombie et al., 2004; Heim et al., 2000; Porter et al., 
2003), we expect patients with high baseline cortisol measurements to show a negative 
change after the intervention and patients with low baseline cortisol measurement to 
show a positive change after the intervention. See specific aim 3 in Subsection 1.2. 
For this reason, we divided the sample population into tertiles of cortisol levels by 
age (< 60 and ≥ 60) and sex at baseline to create an estimate of high, low, and average 
cortisol levels for each individual by age and sex. Because there are only 10 men in the 
sample, and all but 1 are in the greater than 60 age category, men were not further 
divided into age categories before creating tertiles by cortisol level. Using these tertiles 
of the sample population at baseline we create dummy variables 𝑙𝑐 (low cortisol) and ℎ𝑐 
(high cortisol) to classify patients as within the central range (𝑙𝑐 = 0 and ℎ𝑐 = 0), in the 
lower tertile (𝑙𝑐 = 1 and ℎ𝑐 = 0), or in the upper tertile (𝑙𝑐 = 0 and ℎ𝑐 = 1) by sex and 
age (for females). We include this new baseline classification variable in the following 
linear regression models to examine interaction with treatment (𝑡𝑟): 
∆𝐶𝑝,𝑚
1 = 𝛽0𝑚
1 + 𝛽1𝑚
1 𝑡𝑟 + 𝛽2𝑚
1 ℎ𝑐 + 𝛽3𝑚
1 𝑙𝑐 + 𝛽4𝑚
1 (𝑡𝑟×ℎ𝑐) + 𝛽5𝑚
1 (𝑡𝑟×𝑙𝑐) + 𝜀𝑝 
∆𝐶𝑝,𝑚
2 = 𝛽0𝑚
2 + 𝛽1𝑚
2 𝑡𝑟 + 𝛽2𝑚
2 ℎ𝑐 + 𝛽3𝑚
2 𝑙𝑐 + 𝛽4𝑚
2 (𝑡𝑟×ℎ𝑐) + 𝛽5𝑚
2 (𝑡𝑟×𝑙𝑐) + 𝜀𝑝 
We expect 𝛽1𝑚
1 + 𝛽4𝑚
1  and 𝛽1𝑚
2 + 𝛽4𝑚
2   to be significantly less than zero 
(treatment effect for high cortisol level patients) and we expect 𝛽1𝑚
1 + 𝛽5𝑚
1   and 𝛽1𝑚
2 +
𝛽5𝑚
2   to be significantly greater than zero (treatment for low cortisol level patients). All 
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sample calculations are conducted using SAS® 9.4 software, Cary, NC: SAS Institute Inc. 
and the GLM or QUANTREG procedure were used for all regression analyses.
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Chapter 4: Results
4.1 Sample characteristics 
Thirty-eight cancer survivors from GHS were recruited for participation in this 
study. The mean age was 64 years old with a range from 37 to 79. The sample consisted 
of 28 females (74%) and 10 males (26%) and was 84% (32) white and 16% (6) black, with 
one person identifying as ethnically Hispanic. Twenty-nine (76%) participants were 
married, and 9 (24%) were either single, divorced, separated, common law, or widowed. 
Fifty-eight percent of participants had a bachelor’s or higher degree. Select baseline 
demographic and clinical characteristics by group are outlined in Table 4.1 and Table 4.2. 
No significant differences were observed between randomized groups on any measured 
variables except for perceived stress scores; the control group had significantly higher 
perceived stress at baseline than the intervention group (p=0.03). The outcome variables 
assessed are presented in Table 4.3. Average diurnal cortisol decline for the sample group 
was -7.61 nmol/L at baseline, -7.12 at follow-up day 1 and -6.48 at follow-up day 2. From 
average DCD we can see that DCD is increasing through the study period and so we also 
see that change in DCD (∆𝐷𝐶𝐷𝑝
𝑑) is positive, 0.41 and 0.88, for follow-up days 1 and 2 
respectively. Change in cortisol measurements throughout the day from baseline to 
follow-up 1 and 2, though small, are consistently negative. On average, for the entire 
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sample group, both absolute cortisol levels and cortisol decline over the day are 
decreasing. 
Table 4.1. Baseline demographic characteristics of participants across groups 
 
 Intervention Group 
(n=20) 
 
Control Group 
(n=18) 
 
 Meana 
Frequencyb 
(SD) 
(Percent) 
Mean 
Frequency 
(SD) 
(Percent) 
p-value 
Age 63.65 9.80 63.39 12.52 0.47c 
Gender     0.72d 
  Male 6 30% 4 22%  
  Female 14 7% 14 78%  
Race     1.00d 
  Black 3 15% 3 17%  
  White 17 85% 15 83%  
Cohort     0.73e 
  Fall 10 50% 10 56%  
  Winter 10 50% 8 44%  
BMI 25.89 5.02 28.21 6.90 0.27c 
Abbreviations: BMI, Body Mass Index; SD, Standard Deviation 
aMean and Standard Deviation reported for continuous variables 
bFrequency and Frequency % reported for categorical variables 
cp-values from independent t-test 
dp-values from fisher’s exact test 
ep-values from chi-square test 
 
Table 4.2 Baseline clinical characteristics for participants across groups along with value 
interpretations 
 
 Intervention (n=20) Control (n=18) 
p-valuec 
 
 Meana 
Frequencyb 
(SD) 
(Percent) 
Mean 
Frequency 
(SD) 
(Percent) 
Standard Cut 
points 
Physical 
Activity 
    0.41d Scoring based of 
the Rapid 
Assessment of 
Physical Activity 
tool. More active 
categories 
indicate greater 
frequency and 
intensity of 
exercise(Topolski 
et al., 2006) 
Under-active 2 10% 1 6%  
Under-
active, 
Regular-light 
4 20% 1 6%  
Under-
active, 
Regular 
5 25% 3 17%  
Active 9 45% 13 72%  
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Depression      Higher scores 
reflect greater 
symptoms on a 
scale of 0-60. 
Scores above 16 
indicate clinical 
depression 
(Radloff, 1977) 
CESD Score 5.89 4.20 7.71 4.52 0.32 
Stress      Higher scores 
reflect greater 
perceived stress 
on a scale of 0-
40(S. Cohen et 
al., 1983) 
PSS Score 12.61 6.99 18.41 8.16 0.03 
Sleep      A score of 5 or 
greater is 
indicative of poor 
sleep quality (In 
clinical 
populations a 
cutoff of 8 may 
be more 
appropriate)(Beck 
et al., 2004) 
PSQI Score 8.28 4.46 6.19 3.33 0.14 
Cortisol      No standardized 
cut points for 
identifying high 
or low daily 
cortisol levels. 
Units nmol/L 
Average 
Cortisol 
9.64 6.86 9.26 5.15 0.81e 
Abbreviations: CESD, Center for Epidemiologic Studies Depression; PSS, Perceived Stress Scale; PSQI, 
Pittsburgh Sleep Quality Index; SD, Standard Deviation 
aMean and Standard Deviation reported for continuous variables 
bFrequency and Frequency % reported for categorical variables 
cp-values from independent t-test unless otherwise indicated 
dp-value from fisher’s exact test 
ep-values from Wilcoxon Rank Sum Test 
 
Table 4.3 Summary statistics for outcome variables 
 
Outcome 
Variable 
Mean 
Standard 
Deviation 
Minimum Maximum 
Sample Size 
(n) 
𝑫𝑪𝑫𝒑,𝟏 -7.61 6.64 -33.61 6.50 37 
𝑫𝑪𝑫𝒑,𝟐 -7.12 5.22 -29.48 2.29 34 
𝑫𝑪𝑫𝒑,𝟑 -6.48 3.74 -16.33 2.45 33 
∆𝑫𝑪𝑫𝒑
𝟏 0.41 7.59 -17.12 21.62 34 
∆𝑫𝑪𝑫𝒑
𝟐 0.88 7.22 -22.84 23.31 33 
∆𝑪𝒑,𝟏
𝟏  -0.60 6.77 -21.60 18.01 35 
∆𝑪𝒑,𝟐
𝟏  -1.67 6.35 -23.56 9.15 35 
∆𝑪𝒑,𝟑
𝟏  -1.88 5.73 -15.85 9.56 32 
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∆𝑪𝒑,𝟒
𝟏  -0.50 7.36 -26.75 14.24 34 
∆𝑪𝒑,𝟓
𝟏  -0.44 6.86 -34.89 12.29 32 
∆𝑪𝒑,𝟔
𝟏  -0.09 2.48 -6.55 7.74 29 
∆𝑪𝒑,𝟏
𝟐  -0.80 5.84 -21.75 5.87 33 
∆𝑪𝒑,𝟐
𝟐  -1.48 7.27 -20.47 10.16 32 
∆𝑪𝒑,𝟑
𝟐  -0.14 6.91 -13.69 11.78 31 
∆𝑪𝒑,𝟒
𝟐  -0.02 7.31 -24.75 9.19 31 
∆𝑪𝒑,𝟓
𝟐  0.26 7.28 -33.75 16.43 31 
∆𝑪𝒑,𝟔
𝟐  -0.12 2.36 -7.33 4.62 31 
Notes: superscripts on outcome variables indicate follow-up day (1 or 2), subscripts indicate p, patient 
and daily cortisol measurement (1-6) 
Abbreviations: DCD, Diurnal Cortisol Decline; C, Cortisol 
4.2 Baseline Associations with Diurnal Cortisol Decline 
Crude associations with Diurnal Cortisol Decline at baseline are presented in Table 4.4 
and multivariable models are presented in Table 4.5. Only the crude association between sleep 
quality measured using the PSQI sleep index was significant at the alpha=0.1 level in the model at 
baseline but this does not persist when additional variables are included in models 2 and 3. For 
the crude PSQI association, for each 1 unit increase in PSQI score (sleep quality on a scale of 0-21 
with higher scores representing worse sleep quality), baseline DCD increased by 0.63 nmol/L. 
Additionally, the coefficients for crude associations of DCD and gender and activity level are not 
in the direction hypothesized in Subsection 1.2. For activity level, this direction persists in model 
3 with all covariates included – one explanation could be the reference category ‘Under-active’ 
only includes three participants. The other two ‘Under-active’ categories (regular, and regular-
light) are positive relative to the ‘Active’ category as hypothesized. The coefficient for gender 
switches direction when included in the model with other covariates suggesting another measure 
is strongly associated with gender. Also counterintuitive is that increased PSS score and age have 
a negative association with DCD when included with the other variables of interest in model 3, 
though not nearing significance. 
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Table 4.4 Crude association of variables of interest and baseline diurnal cortisol decline 
 
 Coefficient (SE) p-value Sample size (n) 
Physical Activitya    37 
  Under-active, Regular-light 1.15 (5.79) 0.84  
  Under-active, Regular 1.67 (5.47) 0.76  
  Active 0.71 (5.12) 0.89  
Raceb    37 
  Black 1.45 (2.99) 0.63  
Cohortc    37 
  Winter 2.39 (2.18) 0.28  
Genderd    37 
  Female 0.20 (2.49) 0.94  
Age 0.03 (0.10) 0.76 37 
CESD Score 0.39 (0.24) 0.11 35 
PSS Score 0.01 (0.14) 0.95 34 
PSQI Score 0.63 (0.32) 0.06 34 
Abbreviations: CESD, Center for Epidemiologic Studies Depression; PSS, Perceived Stress Scale; PSQI, 
Pittsburgh Sleep Quality Index 
aReference: Under-active 
bReference: White 
cReference: Fall 
dReference: Male 
 
Table 4.5 Three multivariable regression models on variables of interest with baseline Diurnal 
Cortisol Decline 
 
 Model 1 Model 2 Model 3 
 Coefficient 
(SE) 
p-value 
Coefficient 
(SE) 
p-value 
Coefficient 
(SE) 
p-value 
PSQI Score 0.36 (0.43) 0.41 0.39 (0.44) 0.37 0.93 (0.68) 0.19 
CESD Score 0.21 (0.32) 0.52 0.25 (0.34) 0.47 0.30 (0.52) 0.57 
Cohorta       
  Winter   2.42 (2.46) 0.33 4.80 (3.67) 0.21 
Raceb       
  Black   2.54 (3.25) 0.44 3.12 (3.90) 0.43 
Physical Activityc       
  Under-active, Regular-light    9.66 (7.91) 0.24 
  Under-active, Regular    11.21 (7.61) 0.16 
  Active     9.32 (7.56) 0.23 
Age     -0.06 (0.16) 0.69 
Genderd       
  Female     -3.84 (4.03) 0.35 
PSS Score     -0.22 (0.23) 0.35 
Sample size (n) 32 31 30 
R-square 0.08 0.14 0.28 
Abbreviations: CESD, Center for Epidemiologic Studies Depression; PSS, Perceived Stress Scale; 
45 
PSQI, Pittsburgh Sleep Quality Index 
aReference: Fall 
bReference: White 
cReference: Under-active 
dReference: Male 
4.3 Effect of treatment on change in Diurnal Cortisol Decline 
Table 4.6 presents results of the multivariable regression using the GLM procedure with 
outcome variables as change in DCD from baseline to follow-up day 1 and day 2 respectively. We 
used a forward selection method for both models as recommended by the small sample size. 
Potential confounders are listed in Subsection 3.3 and were assessed in the model independently 
with intervention. Cohort and PSS score were included as covariates in both final models. Cohort 
was significant at the α=0.1 level in both models (p=0.03 and p=0.10 for follow-up one and two 
respectively), improved model fit, and had a greater than 10% impact on the coefficient for 
intervention. Perceived Stress, as the only significantly different measured variable at baseline 
between the intervention and control group, was also included in the model. PSS was not 
significant in the model (p=0.71 and p=0.19 for follow-up 1 and 2 respectively with cohort 
included) and did not change inference on intervention from baseline to follow-up 1, but did 
meaningfully attenuate the association between the intervention and change in DCD from 
baseline to follow-up 2. Other potential confounders, though comparable across the intervention 
and control groups at baseline, were assessed individually with the intervention for inclusion in 
the model. PSQI sleep score was significant in the model for follow-up day 1 only, but did not 
change inference on intervention meaningfully (<10% change in the covariate for intervention) or 
improve model fit. Other potential confounders did not approach significance at the α=0.1 level 
or have a meaningful impact on the intervention coefficient, thus only cohort and PSS score were 
included. Treatment showed a non-significant -1.79 nmol/L and -2.71 nmol/L effect on diurnal 
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cortisol decline from baseline to follow-up 1 and 2 respectively when controlling for cohort and 
PSS score. 
Table 4.6 Change in Diurnal Cortisol Decline from baseline to follow-up day indicated (1 or 2) 
 
Follow-up day (d)  1a   2a  
 Coefficient (SE) p-value Coefficient (SE) p-value 
Treatmentb -1.79 (2.72) 0.52 -2.71 (2.22) 0.23 
Cohortc 4.84 (2.65) 0.08 1.79 (2.19) 0.42 
PSS Score -0.07 (0.18) 0.71 0.20 (0.15) 0.19 
R-Squared 0.12 0.18 
Sample Size (n) 32 30 
Abbreviations: SE, Standard Error; PSS, Perceived Stress Scale. 
aAdjusted for cohort and perceived stress scale 
bReference: control group 
cReference: Fall cohort 
4.4 Treatment effect by baseline categorization 
The twelve models assessing change in each of the 6 cortisol measurements from baseline 
to follow-up time 1 and 2 are presented in Table 4.7. Cohort was indicated in the majority of 
models and so was included for all. PSS score was not included as it was not significant and did 
not improve model fit. Results are irregular for the estimates of interest (the combined effect of 
the treatment coefficient and the treatment and baseline categorization level interaction term). 
For the treatment effect for those in the high cortisol category at baseline we observed 7 positive 
estimates and 5 negative estimates, the only significant estimate was positive, opposite the 
direction hypothesized. For the treatment effect for those in the low cortisol category at baseline 
we observed again 7 positive and 5 negative estimates. 
Apart from the effect of interest, from the high cortisol and low cortisol coefficients we 
see that participants categorized at baseline in the high cortisol tertile tended to show decreases 
in cortisol level and those categorized at baseline in the low cortisol tertile tended to show 
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increases in cortisol throughout the study period compared to those in the central tertile when 
adjusting for treatment, cohort, and the treatment and baseline categorization interaction.
  
4
8 
Table 4.7 Standard Multiple Linear Regression or Quantile Regression of change in cortisol from baseline to the follow-up day indicated (1 or 2) 
for each of the 6 cortisol measurements 
 
Measure (m)a 1 (Awakening) 2 (15-min) 3 (30-min) 4 (45-min) 5 (Dinner time) 6 (Bed time) 
Follow-up day (d) 1 b 2 1 2 1 2 b 1 2 b 1 b 2 b 1 2 b 
Sample Size (n) 35 33 35 32 32 31 34 31 32 31 29 31 
 Coefficients (SE) Coefficients (SE) Coefficients (SE) Coefficients (SE) Coefficients (SE) Coefficients (SE) 
Treatment c 
-3.98 
(3.18) 
0.47 
(2.31) 
2.67 
(3.49) 
5.57 
(3.51) 
3.53 
(3.49) 
4.16 
(6.33) 
5.44 
(3.31) 
-0.96 
(4.55) 
-0.05 
(1.09) 
-0.04 
(1.68) 
1.92 
(1.34) 
0.44 
(1.15) 
Tertile at Baseline d            
High Cortisol 
-7.19** 
(3.46) 
-9.70** 
(2.57) 
-6.86** 
(3.32) 
-6.05* 
(3.57) 
-1.99 
(3.60) 
-4.62 
(8.23) 
-11.84** 
(3.69) 
-7.79 
(8.84) 
-0.62 
(1.44) 
-1.57 
(4.19) 
-2.09 
(1.56) 
-0.13 
(3.18) 
Low Cortisol 
0.21 
(4.26) 
-0.24 
(3.18) 
0.81 
(3.85) 
9.13** 
(3.57) 
3.33 
(3.77) 
7.01 
(7.24) 
2.84 
(3.92) 
2.78 
(7.07) 
0.26 
(1.51) 
1.17 
(1.65) 
0.33 
(1.82) 
-0.24 
(1.17) 
Interaction             
Tr × High 
Cortisol 
0.71 
(5.31) 
3.39 
(3.65) 
-1.78 
(4.94) 
-3.72 
(5.02) 
-3.45 
(5.08) 
-4.32 
(9.60) 
4.22 
(4.95) 
0.67 
(10.31) 
0.14 
(2.12) 
0.27 
(5.82) 
-2.05 
(2.11) 
-1.68 
(3.35) 
Tr × Low Cortisol 
4.90 
(4.69) 
0.82 
(3.89) 
-1.86 
(5.54) 
-9.06* 
(5.02) 
-3.19 
(5.24) 
-3.02 
(8.95) 
-7.06 
(5.18) 
-3.63 
(8.06) 
0.37 
(1.61) 
-0.59 
(2.07) 
-2.09 
(2.28) 
0.05 
(1.43) 
Treatment effect by tertile at baseline           
Tr + (Tr × High 
Cortisol) 
-3.27 
(4.17) 
3.85 
(2.85) 
0.88 
(3.39) 
1.85 
(3.50) 
0.08 
(3.52) 
-0.15 
(6.97) 
9.67** 
(3.64) 
-0.28 
(9.72) 
0.09 
(1.54) 
0.23 
(5.01) 
-0.14 
(1.61) 
-1.24 
(2.09) 
Tr + (Tr × Low 
Cortisol) 
0.92 
(3.37) 
1.29 
(3.06) 
0.80 
(3.77) 
-3.48 
(3.20) 
0.35 
(3.85) 
1.14 
(6.46) 
-1.62 
(3.99) 
-4.59 
(6.47) 
0.32 
(1.16) 
-0.63 
(1.56) 
-0.17 
(1.85) 
0.49 
(0.99) 
R-Squared -- 0.57 0.36 0.59 0.19 -- 0.50 -- -- -- 0.34 -- 
Abbreviations; Tr, treatment 
*Indicates significance at the 0.1 level 
**Indicates significance at the 0.05 level 
a All models controlled for cohort 
b Assumptions of linear regression not met; coefficients represent median estimates from quantile regression 
c Reference: control group
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Chapter 5: Discussion
Results of this study did not show a significant impact of CMCS mindfulness 
program on cortisol levels or rhythm. We found that the treatment was associated with 
an increased decline in daily cortisol at both the first and second follow-up compared to 
the control group, but this effect was not significant. When examining effect modification 
of baseline cortisol categorizations on change in cortisol levels over the study period in 
the intervention group compared to the control group, no consistent directional results 
were observed. 
Although not statistically significant, the magnitude of the decrease in cortisol 
decline observed as a treatment effect in our multivariable model examining change in 
daily cortisol decline from baseline to follow-up 1 and 2 was relatively large (-1.79 nmol/L 
and -2.71 nmol/L respectively) compared to the average decline over a day for our sample 
at baseline (-7.61 nmol/L). This is a 23.5% and 35.6% decrease in DCD respectively at 
follow-up 1 and 2 in the intervention group versus the control group when controlling for 
cohort and PSS score. As previously mentioned, several studies have identified a 
significant association between smaller declines in cortisol over the day and decreased 
survival (L. Cohen et al., 2012; Schrepf et al., 2015; Sephton et al., 2013, 2000). 
Unfortunately, these studies consistently use a transformation of raw cortisol values 
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making a comparable estimate of what average absolute or percent change in slope is 
indicative of improved survival outcomes impossible at this time. 
The method we present for examining the effect of an interaction between 
treatment categories of cortisol at baseline was based off of research indicating both 
elevated and depressed cortisol levels are suggestive of HPA axis dysregulation and is 
similar to the approach taken by Bränström and colleagues (Bränström et al., 2013). 
However, we failed to replicate their findings showing significant effect modification of 
treatment by baseline categorization on the awakening timepoint sample (which they 
examined) or to find any similar effect modification on the other 5 diurnal cortisol 
measurements at either follow-up day. It should be noted that their study was 
approximately twice as large as the current study (n-71) and a full 8-week mindfulness 
intervention program was used. 
In the literature, of the seven current studies assessing the effect of a mindfulness 
program on cortisol in a population of cancer survivors, six reported at least one 
significant change in cortisol levels post intervention (Bränström et al., 2013; L. E. Carlson 
et al., 2013; Lengacher et al., 2012, 2012; Lipschitz et al., 2013; Y. Matchim et al., 2011; 
Matousek et al., 2011). The only study that did not report significant changes in cortisol 
levels was also one of two studies that assessed an abbreviated mindfulness program 
(shortened from the original 8-week course) (Lipschitz et al., 2013). As the intervention 
program for our current study was also abbreviated at only 4 weeks and our results were 
not significant, further research is needed to determine what the minimum ‘dose’ of a 
mindfulness program is necessary to create meaningful change. Furthermore, in the 
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current literature, most changes in cortisol post mindfulness intervention were shown for 
a single measure of cortisol rather than for cortisol rhythm (such as the diurnal decline or 
awakening response), even when multiple cortisol samples were collected (Bränström et 
al., 2013; Lengacher et al., 2012; Y. Matchim et al., 2011; Witek-Janusek et al., 2008). This 
gap in the current literature was one that our current study aimed to address, but may 
have had too small a sample size or too short an intervention to show change in cortisol 
rhythm that could be confidently attributed to the mindfulness practice. In the single 
study that did assess the effect of a mindfulness intervention on diurnal cortisol decline 
in cancer survivors (and the largest study to date), Carlson and colleagues found that 
participation in the mindfulness intervention significantly attenuated loss of decline from 
baseline to post intervention compared to the control group (L. E. Carlson et al., 2013). 
As briefly touched on through comparison with the current literature, our study 
has a few apparent limitations to consider. The sample size is relatively small; cortisol was 
measured over only one day at each follow-up time, and although survey response was 
complete and cortisol sampling compliance was high, some missing cortisol 
measurements and missing questionnaire sections further reduced our sample size. 
Additionally, the mindfulness intervention was abbreviated from the established 8-week 
course to 4-weeks for this study. Although there is value in understanding what minimum 
dose of the intervention can be effective, this truncation may have contributed to our 
inconclusive findings. Finally, survivors were not screened for distress as a requirement 
for enrollment; if cortisol levels for our patients were not disrupted at the onset of the 
program there was no way for the CMCS program to lead to improvement.  
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Some strengths of this study are also evident.  As an RCT, the potential for 
confounding from both measured and unmeasured variables is low and we have a high 
potential to provide results that suggest causality. Also, loss-to follow-up was low; only 
two of 38 participants dropped from the program, and follow-up time was moderately 
long (3 months). Additionally, cortisol collection method included enough daily samples 
to assess both absolute levels of cortisol throughout the day and rhythm or decline 
throughout the day. Finally, this study included both men and women with various cancer 
diagnoses – many studies of mindfulness in cancer survivors primarily include only 
women with breast cancer. 
Our results contribute to the accumulation of research surrounding mindfulness 
practice in cancer survivors, but even within this study there is much left to explore; 
potentially a more streamlined approach to examine cortisol levels. Beyond this specific 
work, the field of literature examining associations between mindfulness meditation in 
cancer survivors and health and quality of life outcomes is open to research that uses 
objective measures of these outcomes, and cortisol has strong potential to be used in this 
capacity. 
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